Arazlo is a topical drug designed for the treatment of acne vulgaris in patients aged 9 or older. It is owned by Bausch and came into the market on December 18, 2019. The active ingredient is tazarotene.
Arazlo generic is projected to hit the markets after May 11, 2038. This date comes from the expiry of the last patent, US11311482, on the same day. This patent is specific to Topical Compositions and Methods for Treating Skin Diseases, which Arazlo uses.
Arazlo, containing tazarotene, is primarily used to treat acne vulgaris in patients aged 9 and up. Its topical application helps counter the effects of severe acne and enables the skin surface to rejuvenate.
Arazlo consists of two primary patents. The first, US11679116, titled 'Topical compositions and methods for treating psoriasis', is expected to expire on June 6, 2036. The second patent, US11311482, titled 'Topical compositions and methods for treating skin diseases', will expire on May 11, 2038. This patent will determine the Arazlo generic release date. Below are the details of the patent: